Owen Mumford Publishes Annual Responsible Action Report

Highlighting B Corp Certification and Science-Based Targets Milestones

Owen Mumford (medical device manufactuer) has published its latest annual Responsible Action Report, highlighting progress and achievements in 2021 including its recent B Corp certification and alignment with the Science Based Targets initiative (SBTi) to achieve net zero carbon emissions by 2045, as the company continues to strengthen its sustainability strategy and future-proof its operations.

In June 2021, Owen Mumford was awarded B Corp certification in recognition of its commitment to corporate social responsibility regarding the environment, governance, community engagement, employee support, and customer stewardship. The certification makes Owen Mumford one of the first medical device manufacturers in the world to achieve this, joining over 4,000 global businesses working towards improving their benchmarks and raising standards across all industries.

Sustainability continues to be a key area of focus for Owen Mumford, demonstrated through commitments towards emissions reduction targets with the SBTi. The company has set a target to reach a 50% reduction in carbon emissions by 2030 and become net zero by 2045. Owen Mumford has also joined the Race to Zero movement in 2021, a collaboration of leading companies across the globe supporting efforts to achieve zero carbon recovery.

The report charts the organization’s progress against its chosen United Nations Sustainable Development Goals (SDGs), covering a variety of well-being, infrastructural, and responsible consumption themes. Highlights for 2021 include continued support for the promotion of women in STEM subjects through local collaboration with schools and colleges, to continued evaluation of its logistics output to reduce carbon emissions and lead times to customers. Other initiatives support the company’s commitment to its associates, customers, products, and the planet.

“This past year has been challenging for us all as we entered the second year of the pandemic. Thankfully, 2021 marked a year of growth, action and above all else, resilience for Owen Mumford. Whether achieving B Corp certification, committing to reducing our emissions footprint, or continuing investment in more sustainable products, we have a great deal to be proud of,” said Jarl Severn, CEO of Owen Mumford.

He concluded, “Our goal is to continue with a positive influence on the medical device industry, leading by example on how products should be responsibly made, companies should be ethically run, and futures should be protected. I hope that the hard work and commitment from everyone at Owen Mumford encourages other companies and individuals to implement their own action plans and work towards a better future for everyone.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy